Hotpennystocknews.com is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
Los Angeles, CA -- (SBWIRE) -- 01/16/2014 -- Hotpennystocknews.com issues special report on - World Health Energy Holdings, Inc.(WHEN),Advanced Medical Isotope Corporation (OTCBB: ADMD),Affymax, Inc.(OTCMKTS:AFFY),China Biopharma Inc. (OTCMKTS:CHBO)
World Health Energy Holdings, Inc.(WHEN) , is a development-stage company. The Comapny is an energy tech company providing lean green energy and pioneering new food crops. The Company's products include Spirulina Flakes, Dried Spirulina, Algae Oil for Biodiesel, and Neochloris for Omega 3. In addition to the production of biodiesel, the Company plans to design and manufacture biodiesel production plants in varying capacities. World Health Energy, Inc. (WHE) is a wholly owned subsidiary of the Company. WHE also focuses to establish biodiesel production operations and to acquire alliances, partnerships and joint ventures with other like-minded parties interested in biodiesel technology.
More Details On WHEN, Click Here.
Advanced Medical Isotope Corporation (OTCBB: ADMD) is a late stage development company engaged primarily in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications. AMIC's focus is on transitioning to full operations upon receipt of expected FDA clearance for its patented brachytherapy cancer product, yttrium-90 RadioGel(TM). AMIC intends to file FDA premarket notifications for two related yttrium-90 brachytherapy products. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. Annual sales of brachytherapy products exceed $1 billion, about half of which are in the United States. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans.
To learn more about Advanced Medical Isotope Corporation, visit here.
Affymax, Inc.(OTCMKTS:AFFY) is a biopharmaceutical company engaged in developing drugs to improve the treatment of serious and often life-threatening conditions. Its product candidate, peginesatide, is for the treatment of anemia in chronic kidney disease patients on dialysis. Peginesatide is a synthetic peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a worldwide collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited (Takeda). As of December 31, 2011, over 2,600 patients have received peginesatide in clinical trials. As of December 31, 2011, The New Drug Application (NDA) for peginesatide is under review by the United States, Food and Drug Administration (FDA). As of December 31, 2011, the Company has suspended its development efforts to treat anemia in non-dialysis patients and chemotherapy-induced anemia.
AFFY opened its last trade at the price of $0.95. Its closing price was $0.910 after losing -5.21% for the day. The company traded with the total volume of 340,189.00 shares, while its average trading volume remained 373,110.00 shares. The beta of this stock stands at 1.35.
How AFFY’s stock gained investors attention? Find in this report.
China Biopharma Inc. (OTCMKTS:CHBO) is a provider of pharmaceutical products with its focus mainly on the introduction and marketing of human vaccines and other pharmaceutical products. It has established its distribution and development platform in China and as a result of its acquisition of interest in its majority owned subsidiary, Hainan CITIC Bio-pharmaceutical Development Co., Ltd. (HCBD) and, as a result of its joint venture with Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd. (Zhejiang Tianyuan). It has two operational segments. One segment, consisting of CBL and its subsidiaries provides bio-pharmaceutical products. The other segment, which consists of China Quantum Communication Limited (CQCL) and its subsidiary, was engaged in the business of providing telecommunications services and developing related technology. However, following its re-positioning of its business focus from telecommunications to pharmaceutical operations, CQCL ceased carrying on any daily business activities.
For more depth details, free sign up here.
Neither Hotpennystocknews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by Hotpennystocknews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.Hotpennystocknews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through Hotpennystocknews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in.
Read Full disclaimer at:http://www.hotpennystocknews.com/disclaimer.php
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)